Education
About Us
Working with TipRanks
Follow Us
BB Biotech AG (GB:0JYO)
LSE:0JYO
0JYO Stock Chart & Stats
CHF49.10
-CHF0.25(-0.68%)
At close: 4:00 PM EST
CHF49.10
-CHF0.25(-0.68%)
Day’s Range― - ―
52-Week RangeCHF24.50 - CHF49.60
Previous CloseN/A
Volume269.00
Average Volume (3M)11.11K
Market Cap
CHF2.59B
Enterprise ValueCHF2.60B
Total Cash (Recent Filing)CHF2.16M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)15.8
Beta1.03
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,400,000
10 Day Avg. Volume20,251
30 Day Avg. Volume11,107
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)0.85
Price to Sales (P/S)17.44
P/FCF Ratio6.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sector-focused Investment VehicleA dedicated biotech investment vehicle concentrates domain expertise and research resources on one sector, enabling informed stock selection and thematic exposure. Over months this focused approach supports the potential for outperformance through active allocation to innovation and catalyst-driven winners.
Rebound In 2024 Profitability And Cash FlowSustained positive net income and stronger operating cash flow in 2024 indicate improved portfolio realization and cash generation capacity. Over the medium term this enhances financial flexibility, reduces forced asset sales, and supports reinvestment or distributions without increasing leverage materially.
Strengthened Operating And Free Cash FlowRecovering and meaningful free cash flow creates a durable buffer for an investment vehicle: it funds dividends, covers operating costs, and provides dry powder for opportunistic purchases. Over several quarters, stronger cash flow reduces liquidity risk during biotech market drawdowns.
Bears Say
High Historical Volatility Of ResultsMarked multi-year volatility shows portfolio valuations and operating metrics swing widely with biotech cycles. This structural volatility complicates forecasting, may force realizations at unfavorable times, and weakens predictability of NAV and income across 2–6 months.
Unpredictable Revenue And Earnings ProfileLarge revenue and earnings swings reflect dependence on timing of portfolio events and valuation shifts. Over the medium term this undermines reliable earnings streams and makes distribution planning and long-term performance assessment dependent on episodic realizations rather than steady operational income.
Performance Tied To Biotech Market And ConcentrationAs an actively managed, concentrated biotech portfolio, long-term returns hinge on market cycles and stock-picking skill. This structural dependence increases idiosyncratic and sector cyclicality risk, limiting diversification benefits and making performance sensitive to manager decisions and biotech sentiment over months.
BB Biotech News
0JYO FAQ
What was BB Biotech AG’s price range in the past 12 months?
BB Biotech AG lowest share price was CHF24.50 and its highest was CHF49.60 in the past 12 months.
What is BB Biotech AG’s market cap?
BB Biotech AG’s market cap is CHF2.59B.
When is BB Biotech AG’s upcoming earnings report date?
BB Biotech AG’s upcoming earnings report date is Apr 24, 2026 which is in 78 days.
How were BB Biotech AG’s earnings last quarter?
Currently, no data Available
Is BB Biotech AG overvalued?
According to Wall Street analysts BB Biotech AG’s price is currently Overvalued.
Does BB Biotech AG pay dividends?
BB Biotech AG does not currently pay dividends.
What is BB Biotech AG’s EPS estimate?
BB Biotech AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BB Biotech AG have?
BB Biotech AG has 55,400,000 shares outstanding.
What happened to BB Biotech AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BB Biotech AG?
Currently, no hedge funds are holding shares in GB:0JYO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Options Prices
Currently, No data available
---